TITLE

Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?

AUTHOR(S)
Nattel, Stanley
PUB. DATE
September 2004
SOURCE
CMAJ: Canadian Medical Association Journal;9/28/2004, Vol. 171 Issue 7, p752
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents an analysis of antiarrhythmic drug therapy for atrial fibrillation based on the Canadian Registry of Atrial Fibrillation. Drugs used for the therapy; Need for safer drugs; Information on the patients who underwent antiarrhythmic drug therapy; Knowledge accumulated on the therapy that can help physicians.
ACCESSION #
14423951

 

Related Articles

  • Clinical Pharmacology of Dronedarone: Implications for the Therapy of Atrial Fibrillation. Dorian, Paul // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2010 Supplement, Vol. 15 Issue 4, p15S 

    Dronedarone, a recently approved antiarrhythmic agent, is a chemical analog of amiodarone. It has an approximately 15% bioavailability, with plasma concentrations markedly increasing after a high-fat meal; it is recommended to be taken with food. The primary metabolic clearance pathway for...

  • Dofetilide: A Review of its Use in Atrial Fibrillation and Atrial Flutter. McClellan, K.J.; Markham, A. // Drugs;Dec1999, Vol. 58 Issue 6, p1043 

    Dofetilide is a ‘pure’ class III antiarrhythmic agent which has demonstrated efficacy in the conversion of atrial fibrillation or flutter to sinus rhythm and the maintenance of sinus rhythm. By blocking the rapid component of the cardiac delayed rectifier potassium current (I),...

  • Amiodarone for Atrial Fibrillation. Kirchner, Jeffrey T. // American Family Physician;12/15/2000, Vol. 62 Issue 12, p2685 

    Presents a study by P.E. Vardas and others to evaluate the efficacy and safety of amiodarone in the treatment of atrial fibrillation of long or short duration. Description of the study and its results; Conclusion that amiodarone is a safe and effective method for termination of atrial fibrillation.

  • Amiodarone for the Treatment of Atrial Fibrillation. Kirchner, Jeffrey T. // American Family Physician;9/1/2000, Vol. 62 Issue 5, p1155 

    Presents information on a study by D. Roy and others comparing amiodarone with sotalol and propafenone in the prevention of recurrent atrial fibrillation. Description of the study and its results; Conclusion that amiodarone is significantly more effective than sotalol or propafenone in...

  • No difference after ablation found in patients treated with antiarrhythmic drugs.  // Cardiology Today;May2011, Vol. 14 Issue 5, p17 

    This article discusses a clinical trial on atrial fibrillation in patients treated with antiarrhythmic drugs.

  • Antiarrhythmic for atrial fibrillation and flutter.  // Modern Medicine;Mar96, Vol. 64 Issue 3, p33 

    Reports on the marketing approval given Ibutilide fumarate, an antiarrhythmic drug for atrial fibrillation or atrial flutter. Duration of potency; Side effects.

  • Antiarrhythmic drug therapy in treating AF. McBride, Brian F. // Cardiology Today;Dec2009, Vol. 12 Issue 12, p9 

    The article discusses the use of antiarrhythmic drug therapy in patients with atrial fibrillation in the U.S.

  • Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials. Duray, Gabor Z.; Schmitt, Jörnn; Hohnloser, Stefan H. // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2010 Supplement, Vol. 15 Issue 4, p19S 

    Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF). The phase II Dronedarone...

  • Atrial Fibrillation-The Final Frontier. Govindan, Malini; Savelieva, Irina; Catanchin, Andrei; Camm, A. John // Journal of Cardiovascular Pharmacology & Therapeutics;Dec2010 Supplement, Vol. 15 Issue 4, p36S 

    Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and represents a significant health care issue. The diagnosis and management of AF uses a significant proportion of the health care budget and is responsible for substantial morbidity and mortality. Restoration and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics